USZ0 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Revenue ReboundThe sharp FY2026 revenue rebound indicates improved commercial traction and a materially larger operating base than the prior year. If this higher level is sustained, it could provide greater scale for the business and create a foundation for future margin improvement.
Larger Asset BaseGrowth in total assets shows that the company expanded its balance-sheet resource base during FY2026. While assets alone do not establish profitability, the increase may support operations and commercialization as the company works to convert its stronger revenue level into a more sustainable business.
Improving Free Cash FlowFree cash flow improved compared with FY2025, suggesting some progress in the company’s cash profile despite continued cash burn. This is only an early positive because cash flow remains negative, but further improvement would reduce the funding burden and support greater operating resilience.
Bears Say
Negative Gross Profit And MarginsNegative gross profit means the company is not yet covering direct costs through revenue, while a net margin near -52% confirms substantial losses after operating expenses. Without a demonstrated path to positive gross margins, revenue growth may not translate into durable earnings or self-funded expansion.
Negative Shareholders’ EquityPersistent negative equity signals significant balance-sheet strain and reduces financial flexibility. It can increase recapitalization risk if losses continue, while also making leverage measures less informative and leaving fewer internal resources available to absorb setbacks or fund future investment.
Persistent Cash BurnMaterially negative operating and free cash flow show that current operations are not funding the business. Continued cash burn increases reliance on external funding and can constrain investment, making the company more vulnerable if financing becomes less available or losses persist.
Stemcell United Ltd. News
USZ0 FAQ
What was Stemcell United Ltd.’s price range in the past 12 months?
Currently, no data Available
What is Stemcell United Ltd.’s market cap?
Stemcell United Ltd.’s market cap is €1.46M.
When is Stemcell United Ltd.’s upcoming earnings report date?
Stemcell United Ltd.’s upcoming earnings report date is Mar 04, 2027 which is in 167 days.
How were Stemcell United Ltd.’s earnings last quarter?
Stemcell United Ltd. released its earnings results on Aug 31, 2026. The company reported -$0.002 earnings per share for the quarter.
Is Stemcell United Ltd. overvalued?
According to Wall Street analysts Stemcell United Ltd.’s price is currently Undervalued.
Does Stemcell United Ltd. pay dividends?
Stemcell United Ltd. does not currently pay dividends.
What is Stemcell United Ltd.’s EPS estimate?
Stemcell United Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Stemcell United Ltd. have?
Stemcell United Ltd. has 235,348,460 shares outstanding.
What happened to Stemcell United Ltd.’s price movement after its last earnings report?
Stemcell United Ltd. reported an EPS of -$0.002 in its last earnings report. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Stemcell United Ltd.?
Currently, no hedge funds are holding shares in DE:USZ0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Stemcell United Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
176.07%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Stemcell United Ltd.
BPH Global Ltd, along with its associated entities, specializes in the procurement, production, promotion, and sale of traditional medicinal items. Its operational reach spans Australia, Singapore, China, and the broader Southeast Asian market. The company's diverse product range features both unprocessed and refined bird's nest offerings, alongside marine botanicals like Caulerpa Lentillifera (sea grapes) and various seaweeds. These products are utilized across multiple industries, including food, nutrition, healthcare, dietary supplements, cosmetics, and personal care. Headquartered in Melbourne, Australia, the company was founded in 1984 and transitioned to its current name, BPH Global Ltd, in June 2023, having previously been known as Stemcell United Limited.
Cynata Therapeutics Limited
―
Living Cell Technologies
―
Mesoblast Limited
―
Orthocell Ltd
―
Regeneus Ltd.
―